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ABSTRACT
We have previously reported that an adenosine deam-
inase (ADA)-deficient patient treated with T cell-directed
gene therapy had an increase in serum IgE levels,
despite a marked inversion of the CD4/CD8 ratio. In
the present report, we have analyzed the phenotypic
and functional profiles of the patient’s lymphocytes
obtained during the clinical trial. In peripheral blood
mononuclear cells (PBMC) that were freshly prepared
from the patient, both CD4+ and CD8+ T cell subsets
were negative for CD40 ligand (CD40L; CD154) and
Fas ligand (FasL; CD95L), while CD20+ B cells con-
stitutively expressed CD40 and HLA-DR and were
negative for CD80, CD86 and Fas (CD95). The expres-
sion of CD23 was detected on the majority of CD20+
B cells and expression was upregulated by interleukin
(IL)-4. Furthermore, the patient’s PBMC, which already
expressed both germline and mature Ce transcripts 
in vivo, spontaneously secreted IgE and responded to 
IL-4 with increased IgE production during in vitro
culture. When stimulated with anti-CD3e monoclonal
antibody (mAb), CD8+ T cells from gene-transduced 
T cells displayed high production of interferon (IFN)-g,
low production of IL-4 and IL-13 and comparable
levels of CD40L and FasL expression; however, lined
CD8+ T cells from circulating T cells expressing the
transgene produced IL-4 and IL-13 together with
smaller amounts of IFN-g and preferably expressed
CD40L rather than FasL. Two such CD8+ T cells, in con-
junction with the presence of IL-4, supported CD40L-
mediated B cell proliferation and IgE production after
stimulation and fixation. These results indicate that
ADA-deficient B cells are functionally mature and that
gene-transduced CD8+ T cells and lined CD8+ T cells
containing the transgene exhibit T helper 0- and T cyto-
toxic (c) 2-like phenotypes, respectively. Our data also
suggest that immuno-logic reconstitution with geneti-
cally modified CD8+ T cells may promote IgE production.
Key words: CD40 ligand, CD8+ T cells, gene therapy,
IgE production, interleukin-4.
INTRODUCTION
Adenosine deaminase (ADA) is a purine catabolic
enzyme that catalyzes the conversion of adenosine and
deoxyadenosine to inosine and deoxyinosine, respec-
tively. The accumulation of intracellular adenosine and
deoxyadenosine caused by a genetic defect in ADA leads
to a disability of the human immune system, resulting in
severe combined immunodeficiency characterized by
defective T and B cell function.1,2 On the basis of the
development of gene therapy procedures for the treat-
ment of genetic disorders, 11 patients with ADA defic-
iency have been enrolled in gene therapy protocols that
have used different strategies, retroviral vector constructs
and target cell populations.3–7 The results obtained from
these clinical trials have shown that gene transfer and
expression successfully restore cellular and humoral
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immune responses. The patients enrolled in the gene
therapy trials included a Japanese boy who received infu-
sions of gene-corrected autologous T cells, the majority
of which were positive for CD8. Quite unexpectedly, we
found that he had an elevated serum IgE level and
eosinophilia during the course.8 We also showed that his
circulating CD8+ T cells expressed mRNA for some 
T helper 2 (Th2)-type cytokines following activation.
Although such in vivo and in vitro observations have 
not been described in the other 10 patients, the data
obtained in our patient raised the possibility that
immunologic reconstitution with genetically modified
CD8+ T cells may contribute to increased IgE production
and eosinophilia.
Although CD8+ T cells play a role in protective immu-
nity against viral infections and intracellular pathogens,
recent studies have provided evidence that CD8+ T cells
support B cell antibody production, like CD4+ T cells.9–12
The CD8+ cytotoxic T cells can be divided into two dis-
tinct cytokine-secreting subsets, Tc1 and Tc2, which are
similar to the CD4+ Th1 and Th2 cells.13 The Tc1 cells
produce Th1-type cytokines, such as interferon (IFN)-g
and lymphotoxin, while Tc2 cells, with reduced cytolytic
activity, secrete Th2-type cytokines, including interleukin
(IL)-4, IL-5 and IL-13. The Tc2 cells also provide a costim-
ulatory signal for B cell isotype switching by express-
ing CD40 ligand (CD40L, CD154).11,14 The CD8+ 
T cells with a Tc2 phenotype have been described in
patients with lepromatous leprosy, leishmaniasis, AIDS or
atopy.9,11,12,15,16 In addition to these patients, our ADA-
deficient patient may have had Tc2-like CD8+ T cells
during the gene therapy clinical trial, as recently
reported.8 In the present study we analyzed the pheno-
typic and functional profiles of the patient’s circulating
lymphocytes in more detail.
METHODS
Gene therapy for an ADA-deficient patient
The present study was performed in a boy with ADA defi-
ciency who received periodic infusion of culture-
expanded autologous T cells that had been transduced
with the human ADA cDNA containing the retroviral
vector.7 At the age of 4 years, the boy was enrolled in 
a clinical gene therapy trial and received a total of 
11 infusions over a 20 month period. Before gene
therapy, the patient had very low levels of CD3+ cells
(400 /mL), CD4+ cells (205 /mL), CD8+ cells (191 /mL)
and CD19+ cells (57 /mL) in his peripheral blood.
Following commencement of the trial using genetically
modified T cells, the patient’s circulating CD8+ cells
increased gradually and accounted for approximately
90% of all CD3+ cells after several infusions. This
response has been sustained by the 11th infusion 
(CD3 1822 /mL; CD4 240 /mL; CD8 1538 /mL; CD19
154 /mL). Despite the marked inversion of the CD4/CD8
ratio, the patient had an elevated serum IgE test level,
positive IgE radioallergosorbent (RAST) to house dust
mites and eosinophilia. Details of the data have been
described elsewhere.8 In the present study, we conducted
phenotypic and functional analyses of the patient’s 
circulating lymphocytes obtained before each of the 8th 
to 11th infusions. Informed consent was obtained from
his parents.
Cell preparation
Heparinized venous blood was taken from the patient
and healthy adults with no history of allergy and also
atopic adults with bronchial asthma or perennial allergic
rhinitis. Peripheral blood mononuclear cells (PBMC) were
separated by Ficoll–sodium metrizoate sedimentation
(Organon Teknika Corp., Durham, NC, USA). Depletion
of CD2+, CD4+, CD8+, CD14+, CD19+ and/or CD56+
cells from PBMC or the transduced cells was performed
using magnetic beads coated with appropriate mono-
clonal antibodies (mAbs) or streptavidin (Dynal, Oslo,
Norway), as described previously.17 Purity of CD20+ B cells
obtained by treating PBMC was always > 98% as deter-
mined by flow cytometry. The CD8+ T cell subset isolated
from transduced cells contained no detectable CD4+,
CD20+ or CD56+ cells. The adult donors used for collec-
tion of peripheral blood gave informed consent to
participate in the study.
Generation of CD8+ T cell lines
The patient’s PBMC were suspended at a concentration
of 1 · 106 cells/mL in RPMI 1640 medium (Gibco BRL,
Grand Island, NY, USA) with 10% fetal calf serum 
(FCS), 2 mmol/L L-glutamine, 100 U/mL penicillin and
100 mg/mL streptomycin. Cells were then stimulated 
with 1 mg/mL phytohemagglutinin (PHA)-P (Serva, Heidel-
berg, Germany) and 20 U/mL IL-2 (Genzyme Corp.,
Cambridge, MA, USA) in 24-well flat-bottomed plates
(Becton Dickinson Labware, Lincolon Park, NJ, USA), as
described in detail elsewhere.9 In order to generate T cell
lines, viable T blasts were cultured in bulk with the addi-
tion of IL-2. After analysis of the surface expression of 
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T cell markers, several CD8+ T cell lines were grown and
two cell lines containing the transgene were finally selected.
The transgene-carrying cells were evaluated exactly as des-
cribed previously.7 Phenotypic analysis showed that both
cell lines were positive for CD3, CD8 and T cell receptor
(TCR)-a,b (> 99%), but negative for CD4, CD56 and
TCR-g,d (< 1%). Lined CD8+ T cells were rested in culture
medium for at least 48 h after the last addition of IL-2.
Cytokine assays
Immunoreactive IFN-g, IL-4 and IL-13 were quantitatively
assayed with commercially available ELISA kits (BioSource
International, Camarillo, CA, USA) according to the
manufacturer’s instructions. The sensitivity of each assay
was 7.8 pg/mL.
Flow cytometric analysis
For one-color immunofluorescence staining, cells were
labeled with appropriate concentrations of fluorescein
isothiocyanate (FITC)/phycoerythrin (PE)-conjugated mAbs
or incubated with biotinylated mAb and PE-conjugated
streptavidin. For two-color immunofluorescence staining,
cells were labeled with two different mAbs conjugated
with FITC or PE, or incubated with biotinylated mAb fol-
lowed by PE-conjugated streptavidin and FITC-conjugated
mAb. The mAbs used were anti-CD3, anti-CD4, anti-
CD8, anti-CD20, anti-HLA-DR (all from Becton Dickinson,
San Jose, CA, USA), anti-CD40 (Serotec, Oxford, UK),
anti-CD80, anti-CD86 (two from PharMingen, San Diego,
CA, USA), anti-Fas (anti-CD95, Medical & Biological
Laboratories, Nagoya, Japan), anti-CD40L (anti-CD154;
Ancell, Bayport, MN, USA), anti-FasL (anti-CD95L; Trans-
duction Laboratories, Lexington, KY, USA) and anti-CD23
that was the same as described previously.17 Isotype-
matched control mAbs were used for negative staining.
Stained cells were analyzed by flow cytometry on a
FACScan (Becton Dickinson) using a gate for lymphocytes.
Spontaneous and IL-4-induced production 
of IgE
Measurement of IgE synthesis was conducted as
described previously.17 The patient’s PBMC were sus-
pended at a concentration of 1 · 106 cells/mL in Iscove’s
modified Dulbecco’s medium (Gibco BRL) supplemented
with FCS, L-glutamine and antibiotics (culture medium).
Aliquots of the cell suspension in a total volume of 0.2 mL
were cultured in 96-well round-bottomed plates (Coastar
Corp., Cambridge, MA, USA) with or without 200 U/mL
IL-4 (Genzyme Corp.) for 14 days. To estimate preformed
IgE, both cycloheximide and puromycin were added to
some cultures. The concentration of IgE in culture super-
natants was measured by an isotype-specific radio-
immunoassay. Net IgE synthesis was calculated by 
subtracting the value of preformed IgE.
Coculture experiments
Transduced or lined CD8+ T cells at a density of 1 · 106
cells/mL were stimulated for 24 h with or without 100
ng/mL anti-CD3e mAb (PharMingen), followed by fixa-
tion with 0.5% paraformaldehyde. Fixed cells (1 · 105
cells) were incubated in the presence of 200 U/mL IL-4
with purified normal human B cells (1 · 105 cells) in a
total volume of 0.2 mL in culture medium. Aliquots of the
cell suspension were dispensed into 96-well round-
bottomed plates and cultured for either 3 (B cell prolifer-
ation) or 14 days (IgE synthesis). For the B cell proliferation
assay, cultures were pulsed for 12 h with [3H]-thymidine
(18.5 kBq/mL; Amersham Japan, Tokyo, Japan). In some
experiments, wells had a chimeric molecule (20 mg/mL)
generated by fusing the extracellular domain of human
CD40 to the heavy chain of human IgM (soluble form of
CD40; kindly provided by Dr P Lane, Basel Institute for
Immunology, Basel, Switzerland).18
Reverse transcription–polymerase chain 
reaction analysis
Extraction of total cellular RNA, cDNA synthesis by reverse
transcription (RT) and polymerase chain reaction (PCR)
were performed as described previously.19 The 5¢ sense
primers and 3¢ antisense primers used for amplification of
mRNA for IL-4, IL-13, CD40L, FasL, germline Ce, mature
Ce and glyceraldehyde 3-phosphate dehydrogenase
(G3PDH) were the same as described previously.17 Primer
pairs specific for IFN-g were obtained from Clontech
Laboratories (Palo Alto, CA, USA). The reactions were all
within the linear range. The PCR products were separated
on a 2% agarose gel and stained with ethidium bromide.
RESULTS
Phenotypic and functional analyses of PBMC
from an ADA-deficient patient treated with
gene therapy
An ADA-deficient patient received a total of 11 infusions of
transduced T cells. Before each of the last four infusions,
INDUCTION OF IgE SYNTHESIS BY CD8+ T CELLS 197
PBMC were isolated from the patient, stained with mAbs
and analyzed by flow cytometry. The results of cell surface
marker analysis performed before the 8th gene therapy
are shown in Fig. 1a. The PBMC contained CD3+ T cells
with a CD4/CD8 ratio of approximately 0.1. This marked
inversion was sustained by the 11th gene therapy (data
not shown). Both CD4+ and CD8+ T cell subsets were
negative for CD40L and FasL, while CD20+ B cells that
remained in the normal range constitutively expressed
CD40 and human lymphocyte antigen (HLA)-DR, but no
CD80, CD86 and Fas. Interestingly, CD23 expression
was detected on the majority of CD20+ B cells. When
stimulated for 48 h with 100 U/mL IL-4, purified B cells
responded by upregulation of CD23, CD40, HLA-DR and
CD86 (Fig. 1b). Although culture alone induced CD86
expression, this may be caused by FCS stimulation.
Both germline and mature Ce transcripts could be
detected by RT-PCR analysis of fresh PBMC obtained
before the 8th gene therapy (Fig. 2a). These two tran-
scripts were detected in fresh PBMC of an atopic subject,
but not in those of a healthy donor. In vivo expression of
germline and mature Ce mRNA in the patient’s PBMC
was sustained throughout the study (Fig. 2b). Further-
more, the PBMC obtained before each of the 8th to 11th
gene therapy sessions spontaneously secreted detectable
amounts of IgE and responded to IL-4 with increased IgE
production (Fig. 3). The concentration of IgE produced
by the patient’s PBMC stimulated with IL-4, which ranged
from 6.6 to 12.8 ng/mL, approximated that produced by
IL-4-stimulated PBMC from healthy donors (mean (± SEM)
9.7 ± 2.2 ng/mL; n = 15). Although these values were
somewhat low compared with those obtained in cultures
of PBMC from atopic donors (17.0 ± 3.9 ng/mL, n = 22),
IgE levels spontaneously secreted by the patient’s PBMC,
which ranged from 0.3 to 1.9 ng/mL, were almost equal
to those secreted by unstimulated PBMC from 22 atopic
donors (2.3 ± 0.9 ng/mL).
Collectively, these results demonstrate that the ADA-
deficient B cells of the patient were functionally mature
with respect to CD23 expression, germline and mature
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Fig. 1 Analysis of the patient’s circulating lymphocytes obtained before the 8th gene therapy session. (a) Two-color staining of
fresh peripheral blood mononuclear cells (PBMC) was done. (b) Purified B cells were cultured for 48 h with medium alone (·········) or
interleukin (IL)-4 (––––) and were singly stained. In each experiment, background staining was obtained by incubating cells with
isotype-matched control monoclonal antibodies (mAbs; ········· in (b)). Cells were analyzed by flow cytometry using mAbs to the indi-
cated cell surface markers. Similar results were obtained in the patient’s PBMC and B cells obtained before the 9th to 11th gene
therapy sessions (data not shown).
Ce transcription and IgE synthesis, despite the marked
inversion of the CD4/CD8 ratio after gene transduction
procedures.
CD8+ T cells from gene-transduced T cells
CD8+ T cells were purified from transduced T cells used
for the 8th infusion, but no selection procedure to enrich
for gene-transduced CD8+ T cells was performed. Cells
were stimulated with or without anti-CD3e mAb and were
analyzed for the capacity to express mRNA for IFN-g, IL-4,
IL-13, CD40L and FasL. As summarized in Fig. 4a, IFN-g
mRNA, which was detected even in unstimulated cells,
increased at 3 h after stimulation and accumulated at 
relatively high levels to 24 h. Interleukin-4 mRNA expres-
sion was transient, beginning as early as within 1 h after
stimulation and declining thereafter. In contrast, dual
expression of IL-13 mRNA was induced after stimulation:
the first peak at 1 h and the second at 12 h. Induction of
CD40L mRNA occurred within as little as 1 h of stimula-
tion, reached a peak at 12 h and declined thereafter. The
increase in FasL mRNA also occurred at 6 h after stimula-
tion. These observations are in keeping with the data
obtained at the protein level, where unstimulated cells
secreted only IFN-g, while stimulated cells produced IFN-
g in larger quantities together with detectable amounts of
IL-4 and IL-13 (Fig. 4b) and expressed surface CD40L
and FasL at almost the same level (Fig. 4c). Similar results
were obtained in CD8+ T cells from transduced cells used
for the 9th, 10th and 11th infusions (data not shown).
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Fig. 2 Analysis of in vivo
expression of germline and mat-
ure Ce transcripts in fresh peri-
pheral blood mononuclear cells
(PBMC). (a) Comparison of germ-
line and mature Ce mRNA
expression in the patient’s PBMC
obtained before the 8th gene
therapy session (lane 1) and
PBMC from an atopic subject
(lane 2) and a healthy donor (lane
3). (b) Expression of germline and
mature Ce mRNA in the patient’s
PBMC obtained before the 8th
(lane 1), 9th (lane 2), 10th (lane
3), and 11th (lane 4) gene therapy
sessions. In each experiment, total
cellular RNA was prepared and
the expression of mRNA for
germline Ce, mature Ce and
glyceraldehyde 3-phosphate de-
hydrogenase (G3PDH) was
analyzed by reverse transcription–
polymerase chain reaction.
Fig. 3 Spontaneous and interleukin (IL)-4-induced produc-
tion of IgE by the patient’s peripheral blood mononuclear cells
(PBMC). Cells obtained before each of the 8th to 11th gene
therapy sessions were cultured for 14 days in the absence (s)
or presence (d) of IL-4. The concentration of IgE in culture
supernatants was measured by an isotype-specific radioim-
munoassay. Net IgE synthesis was determined by subtracting
the value of preformed IgE. Results are the mean ± SEM of
triplicate cultures.
These results suggest that the properties of CD8+ T cells
from the transduced cells may be similar to those of 
Th0-type CD4+ T cells.
Lined CD8+ T cells from peripheral T cells car-
rying the transgene
Two lined CD8+ T cells containing the transgene were
generated from PBMC obtained before the 10th gene
therapy session, but no selection procedure to enrich for
transgene-expressing CD8+ T cell lines was performed.
Such lined CD8+ T cells were cultured in the absence or
presence of anti-CD3e mAb for 24 h and analyzed for
the capacity to produce IFN-g, IL-4 and IL-13 and to
express CD40L and FasL. A representative result is shown
in Fig. 5. After being stimulated, cytokine production
increased in the order of IFN-g < IL-4 < IL-13 (Fig. 5a).
Surface expression of CD40L was also detected on stim-
ulated cells, whereas induction of FasL expression was
very weak (Fig. 5b). These results imply that, to some
extent, lined CD8+ T cells containing the transgene
exhibit a Tc2-like phenotype.
B Cell proliferation and IgE synthesis induced
by CD8+ T cells from transduced cells and cell
lines
Before the 10th gene therapy session, both transduced
and lined CD8+ T cells were prepared as described.
These two kinds of CD8+ T cells were stimulated with or
without anti-CD3e mAb, fixed in paraformaldehyde and
added to normal human B cells, followed by culture in the
presence of IL-4. The results are summarized in Fig. 6.
Although none of the unstimulated CD8+ T cells had any
ability to help B cells, stimulated lined cells provided
B cell proliferation and help for IgE synthesis more effec-
tively than did stimulated transduced cells. Addition of a
soluble form of CD40 to the cultures led to abrogation of
B cell proliferation and IgE production in each case, indi-
cating the involvement of functional CD40L. Unlike in
lined CD8+ T cells, the optimal concentration of trans-
duced CD8+ T cells for inducing IgE synthesis was 50%,
with higher concentrations of the cells being inhibitory
(data not shown). These results demonstrate that CD40L-
dependent B cell help provided by lined CD8+ T cells was
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Fig. 4 Analysis of CD3-mediated expression of mRNA and protein for interferon (IFN)-g, interleukin (IL)-4, IL-13, CD40L and FasL
in CD8+ T cells transduced with the adenosine deaminase (ADA) cDNA. The CD8+ T cells from transduced cells at the 10th infusion
were stimulated with or without anti-CD3e monoclonal antibody (mAb) and cells and supernatants were harvested at the indicated
time point. (a) After extraction of total cellular RNA, mRNA for the indicated molecules was amplified by reverse 
transcription–polymerase chain reaction (RT-PCR). The PCR products were subjected to electrophoresis and were visualized by ethid-
ium bromide. (b) Supernatants were measured for cytokine concentrations by ELISA kits. Each point represents the mean ± SEM of 
triplicate cultures. (c) Cells were analyzed by flow cytometry using mAbs to the indicated cell surface markers.
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Fig. 5 Production of interferon (IFN)-g, interleukin (IL)-4 and IL-13 and expression of CD40L and FasL by lined CD8+ T cells from
the patient’s peripheral blood mononuclear cells obtained before the 10th gene therapy session. Lined CD8+ T cells were stimulated
for 24 h with or without anti-CD3e monoclonal antibody (mAb) and supernatants and cells were harvested. (a) Supernatants were
measured for cytokine concentrations by ELISA kits. Results are the mean ± SEM of triplicate cultures. Unstimulated cells produced
no detectable cytokines (data not shown). (b) Cells were analyzed by flow cytometry using mAbs to the indicated cell surface markers.
Fig. 6 B Cell proliferation and IgE production induced by CD8+ T cells transduced with the adenosine deaminase (ADA) cDNA
and by lined CD8+ T cells from peripheral T cells carrying the transgene. These two CD8+ T cells were prepared before the 10th
gene therapy session, stimulated for 24 h with anti-CD3e monoclonal antibody and fixed with paraformaldehyde. Normal human B
cells were incubated in the presence of interleukin (IL)-4 with transduced or lined CD8+ T cells for either 3 (B cell proliferation) or 14
days (IgE production). After culture, [3H]-thymidine uptake and IgE concentrations were measured. Results are the mean ± SEM of
triplicate cultures.
potent compared with that provided by transduced CD8+
T cells.
DISCUSSION
In the present study, we investigated the mechanisms
responsible for the elevation of serum IgE levels observed
in an ADA-deficient patient treated with T cell-directed
gene therapy. On the basis of the observation that this
clinical trial led to the marked inversion of the CD4/CD8
ratio due to a favorable balance for CD8+ T cell gene
transduction,7 we analyzed the functional profile of the
patient’s CD8+ T cells obtained during the course of 
the trial. The experiments presented in this study demon-
strate that immunologic reconstitution with genetically
modified CD8+ T cells may promote the generation of
Tc2-like cells that contribute to IgE production by B cells.
When stimulated with anti-CD3e mAb, CD8+ T cells
from transduced T cells produced IFN-g, together with
smaller amounts of IL-4 and IL-13, and expressed com-
parable levels of CD40L and FasL, while lined CD8+
T cells from circulating T cells carrying the transgene pro-
duced IL-4 and IL-13, together with smaller amounts of
IFN-g, and preferably expressed CD40L rather than FasL.
Our data also show that the level of CD40L induction by
the stimulated lined CD8+ T cells correlates with their
level of IL-4 and IL-13 production and with a reduction of
FasL expression. Because CD8+ T cell clones without the
capacity to secrete IL-4 have been reported to fail to
express CD40L,10 it is conceivable and probable that
transduced and lined CD8+ T cells have Th0- and 
Tc2-like phenotypes, respectively. Although the possibility
that transduced CD8+ T cells contained a mixed pop-
ulation of Tc1 and Tc2 cells cannot be ruled out, super-
natants from transduced CD8+ T cells stimulated with
anti-CD3e mAb, as well as those from the stimulated
lined CD8+ T cells, were able to induce germline Ce tran-
scription in normal human B cells (data not shown).
These observations indicate that following immunologic
stimualtion, both transduced and lined CD8+ T cells
produce biologically active IL-4 and/or IL-13.
Furthermore, after stimulation and fixation, lined CD8+
T cells, in conjunction with the presence of IL-4, provided
CD40L-dependent B cell help more effectively than did
transduced CD8+ T cells. The dose–response curve for
CD8+ T cell-induced IgE synthesis showed an optimum at
a concentration of 50% transduced CD8+ T cells, with
higher concentrations of cells being inhibitory, unlike
lined CD8+ T cells. This may be due to differences in FasL
expression between transduced and lined CD8+
T cells. Actually, it has been shown that FasL expression by
subsets of CD4+ and CD8+ T cells is relatively restricted
to Th0, Th1 and Tc1.20–23 Although we did not examine
directly the IgE-inducing activity of the viable stimulated
CD8+ T cells, the observation that both transduced and
lined CD8+ T cells produced biologically active IL-4 
and IL-13 and expressed functional CD40L in response
to anti-CD3e mAb, together with the finding that purified
CD8+ T cells from the patient’s PBMC secreted Th2-type
cytokines following PHA stimulation,8 supports the notion
of a stimulatory effect of Tc2-like CD8+ T cells on IgE pro-
duction by B cells. This may be one of the possible
mechanisms contributing to the elevation of serum IgE
levels in our patient. Because polyethylene glycol (PEG)-
ADA was maintained at the same dosage as before gene
therapy,7 it is also possible that enhancement of in vivo
IgE production may result from a combination of gene
therapy and PEG-ADA. However, it should be empha-
sized that PEG-ADA treatment alone was ineffective in
increasing serum IgE levels.8 These findings strongly
suggest the possibility that genetically modified CD8+
T cells play an important role in acting as a trigger for the
induction of IgE synthesis.
Differential expression of transcription factors, adhe-
sion molecules and chemokine receptors has been
shown in polarized Th1 and Th2 cells.24–29 With regard to
Th2-specific transcription factors, c-MAF and GATA-3
are thought important in transactivating the IL-4 pro-
moter. In contrast to GATA-3, which is also expressed in
Th0 cells, c-MAF is selectively expressed in polarized Th2
cells, particularly in murine CD4+ T cells. Although the
human c-maf sequence has not yet been available,
mouse, rat and chicken have c-maf with a high degree of
sequence homology.24 To examine c-maf expression in 
IL-4-producing human CD8+ T cells, we conducted 
RT-PCR analysis using primer pairs specific for conserved
areas with almost complete sequence homology with
mouse and chicken c-maf. Our preliminary results showed
that both transduced and lined CD8+ T cells, as well as
the murine Th2 clone D10G4.1, constitutively expressed
detectable c-MAF transcripts (K Ikizawa et al., unpubl.
obs., 1999). However, recent studies in human T cells
have demonstrated that the c-MAF binding site does not
appear essential for IL-4 promoter activity30 and that Th1
and Th2 clones have comparable levels of c-maf expres-
sion.29 These findings suggest that c-maf expression may
not always reflect the generation of IL-4-producing human
T cells, including CD4+ and CD8+ T cell subsets. The
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pattern of GATA-3 and chemokine receptor expression in
the two CD8+ T cells used in the present study is currently
being analyzed.
In our patient, transduced CD8+ T cells differentiated
into Tc2-like cells after infusion. Indeed, lined CD8+
T cells from peripheral T cells carrying the transgene pro-
duced IL-4 and IL-13 and expressed CD40L following
stimulation with anti-CD3e mAb. This may explain why
immunologic reconstitution with genetically modified
CD8+ T cells led to enhanced IgE production. Further-
more, because the frequency of ADA cDNA-integrated
cells in peripheral T cells and immunologic improvement
showed a good correlation,31 it is most likely that trans-
duced, rather than untransduced, CD8+ T cells play a
major role in helping B cells to produce IgE. In contrast,
there remains the possibility that the very small CD4+
T cell population in the transduced cells also underwent
in vivo activation to provide help for B cells in IgE pro-
duction. Further investigations are necessary to analyze
the contribution of transduced CD4+ T cells to the regu-
lation of IgE synthesis.
In summary, we show that preferential gene trans-
duction into CD8+ T cells allows the development of
Tc2-like cells that provide help for B cells in IgE synthesis
by producing IL-4 and IL-13, together with smaller
amounts of IFN-g, and by preferably expressing CD40L
rather than FasL. These findings support the notion of a
high frequency of CD8+ T cells with a Tc2 phenotype in
some diseases showing elevated serum IgE levels.
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